Gastrointestinal

Colorectal:

CIRB #H-39558/ CTSU #A021703 (SOLARIS): Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer

CIRB #H-37277/ CTSU #A021502 (ATOMIC): Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Neuroendocrine:

CIRB #H-38045/ CTSU #A021602 (CABINET): Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on on Prior Therapy

CIRB #H-42963/ CTSU #A022001: Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors (pending IRB approval)

WCG IRB #H-41709/ DFCI #19-403: Phase II trial of cabozantinib in combination with nivolumab for advanced carcinoid tumors (temporary closure)

Liver:

IRB #H-42011/ HCRN #GI10-405:: A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Pancreatic:

CIRB #H-40808/ CTSU #A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

CIRB #H-41225/ Partners #Decision Aids: Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes

Stomach:

CIRB #H-42888/ ETCTN #10211: A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer (pending IRB approval)

Esophageal:

CIRB H-42109/ CTSU #EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Metastatic/Advanced 2nd+ Line Solid Tumors:

KRAS/NRAS/HRAS/BRAF positive
CIRB #H-42956/ ETCTN #10449: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (pending IRB approval)